Last reviewed · How we verify
NCT02843607
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
Completed
Phase 1, PHASE2
Last updated 12 September 2019
What this trial tests
Phase 1, PHASE2 trial testing Cryosurgery in Metastatic Renal Cell Cancer in 30 participants. Completed in 1 July 2019.
Timeline
1 July 2016
Primary endpoint
1 July 2017
1 July 2017
1 July 2019
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 July 2016 |
| Primary completion | 1 July 2017 |
| Estimated completion | 1 July 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cryosurgery
- NK immunotherapy — full drug profile →
Conditions studied
- Metastatic Renal Cell Cancer — all drugs for Metastatic Renal Cell Cancer →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 30 to 70, any sex, with Metastatic Renal Cell Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced kidney cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
NK cell-based cancer immunotherapy: from basic biology to clinical development.
Liu S, Galat V, Galat Y, Lee YKA, et al · · 2021 · cited 504× · PMID 33407739 · DOI 10.1186/s13045-020-01014-w -
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038 -
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
Yakkala C, Chiang CL, Kandalaft L, Denys A, et al · · 2019 · cited 67× · PMID 31608067 · DOI 10.3389/fimmu.2019.02283 -
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Fournier C, Martin F, Zitvogel L, Kroemer G, et al · · 2017 · cited 55× · PMID 29147628 · DOI 10.1080/2162402x.2017.1363139 -
NK Cell-Based Immunotherapy in Renal Cell Carcinoma.
Terrén I, Orrantia A, Mikelez-Alonso I, Vitallé J, et al · · 2020 · cited 31× · PMID 32013092 · DOI 10.3390/cancers12020316 -
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy.
Abakushina EV, Popova LI, Zamyatnin AA, Werner J, et al · · 2021 · cited 29× · PMID 34835294 · DOI 10.3390/vaccines9111363 -
Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.
Bugide S, Janostiak R, Wajapeyee N. · · 2018 · cited 29× · PMID 30064663 · DOI 10.1016/j.trecan.2018.06.004 -
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
Sabry M, Lowdell MW. · · 2020 · cited 21× · PMID 32416056 · DOI 10.1002/sctm.19-0423
Verify or expand the search:
- PubMed search for NCT02843607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cryosurgery
Trials testing the same drug.
- NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
- NCT04429204 — Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma · NA · withdrawn
- NCT04693377 — Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T · NA · recruiting
- NCT04249167 — Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer · EARLY_PHASE1 · withdrawn
- NCT04150939 — Cryoablation for the Treatment of Metastatic Cancer · NA · active not recruiting
Other recruiting trials for Metastatic Renal Cell Cancer
Currently open trials in the same condition.
- NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
- NCT03092856 — Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer · Phase 2 · active not recruiting
- NCT02664883 — Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer · active not recruiting
- NCT01590069 — Aerosolized Aldesleukin in Treating Patients With Lung Metastases · Phase 1 · active not recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02843607 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 12 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing